Last checked at 15 May 2020 17:17
e-therapeutics plc
Annual General Meeting - Change of Arrangement
15 May 2020: e-therapeutics plc (AIM: ETX, "e-therapeutics" or the "Company"), the drug discovery company, clarifies arrangements for the upcoming Annual General Meeting ("2020 AGM") that is to be held at 11:00 am on 2 June 2020, the Notice of the 2020 AGM having been published on 31 March 2020.
In response to the current COVID-19 pandemic and stay at home measures in place, and to focus on the safety of our shareholders, employees and the Board, we will make arrangements such that the legal requirements to hold the meeting can be satisfied through the attendance of two Company director shareholders, employee shareholders or an appointed proxy. The 2020 AGM will now be held at 17 Blenheim Office Park, Long Hanborough, Oxfordshire OX29 8LN (which is the Company's registered office) and not at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH. The time and date of the AGM remain as 11:00 am on 2 June 2020 and the business to be conducted remains as set out in the Notice of the AGM.
Any shareholders, except those that are legally required to form a quorum, may not attend the 2020 AGM in person and will be refused entry. Shareholders are strongly encouraged to vote by proxy on the resolutions contained within the Notice of the 2020 AGM in accordance with the instructions printed on the proxy form. Please return your forms as soon as possible and in any event prior to 11:00 am on 29 May 2020 or not less than 48 hours before the time of the meeting or any adjourned meeting. Further information can be found in the Notice of the 2020 AGM on pages 64 to 68 of the Annual Report, a copy of which can be found at https://www.etherapeutics.co.uk/investors/reports-results/.
If you do not have a proxy form and believe that you should have one, or if you have any additional queries on voting, please contact our registrar by email to info@nevilleregistrars.co.uk or by post at Neville Registrars Limited, Neville House, Steelpark Road, Halesowen B62 8HD.
Should a shareholder have a question that they would have raised at the AGM, they can send it by email to contact@etherapeutics.co.uk. Answers to questions will be published on our website following the AGM.
The Board would like to take this opportunity to thank all shareholders for their continued support and understanding in these exceptional circumstances.
-Ends-
For more information, please contact:
e-therapeutics plc Ali Mortazavi, Executive Chairman
| Tel: +44 (0)1993 883 125 www.etherapeutics.co.uk
|
Numis Securities Limited Freddie Barnfield/Duncan Monteith (Nominated Adviser) James Black (Corporate Broking)
| Tel: +44 (0) 207 260 1000 www.numis.com
|
FTI Consulting Simon Conway | Tel: +44 (0) 203 727 1000 Email: e-therapeutics@fticonsulting.com |
About e-therapeutics
e-therapeutics is an Oxford, UK-based company with a unique and powerful computer-based approach to drug discovery, founded on our industry-leading expertise in network biology.
We have created two proprietary, unique and productive technologies. The first is Network-driven Drug Discovery ("NDD"), which is based on cutting-edge network science, statistics, machine learning and artificial intelligence. NDD allows the more efficient discovery of new and better drugs and has been validated in multiple and diverse areas of biology.
The second is Genome Associated Interaction Networks ("GAINs"). GAINs is a revolutionary and entirely novel approach to functional genomics, based on the same validated network biology and analytics expertise that underpins our NDD technologies. GAINs analyses human genetic data to provide a deep and valuable understanding of the mechanisms that cause disease. GAINs has the potential to uncover unrecognised disease processes and pathways and can enable the discovery of novel drugs, diagnostics and biomarkers in a way not previously possible from population genomics data, such as genome-wide association studies ("GWAS").
We have deployed our highly productive drug discovery platform technologies to develop our own IP-protected, pre-clinical drug discovery programmes that are available to partners seeking to acquire or in-license novel and differentiated assets.
We have partnerships with Novo Nordisk in Type-2 diabetes and a US-based, top 5 pharmaceutical company in neurodegeneration. We are working on different types of collaborative partnerships with biotech, pharma and other technology companies to create sustainable mutual value.